New York Blood Center Enterprises buys Talaris’ cell therapy facilities in CDMO expansion

The New York Blood Cen­ter En­ter­pris­es (NY­BCe) is ab­sorb­ing two of Ta­laris Ther­a­peu­tics’ au­tol­o­gous and al­lo­gene­ic cell and gene ther­a­py fa­cil­i­ties to ex­pand its CD­MO ca­pa­bil­i­ties and ge­o­graph­i­cal foot­print in the US.

“We now have all the pieces in the con­tin­u­um of man­u­fac­tur­ing,” NY­BCe CEO Chris Hilly­er told End­points News. 

The blood cen­ter has the busi­ness unit Com­pre­hen­sive Cell So­lu­tions (CCS) with a clien­tele of phar­ma com­pa­nies, biotechs and aca­d­e­m­ic cen­ters. CCS of­fers de­vel­op­ment and man­u­fac­tur­ing of cell and gene ther­a­pies for pre­clin­i­cal and com­mer­cial-stage prod­ucts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.